Incyte Corporation vs Pinterest Inc — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Pinterest Inc trades at $21.4 (market cap $11.63B). The key difference: Incyte Corporation is the larger of the two by market cap, and Incyte Corporation is trading nearer its 52-week high, Pinterest Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Pinterest Inc for 85 Days on average.
| INCY | PINS | |
|---|---|---|
Market Cap | $22.85B | $11.63B |
Volume | 1,927,029 | 12,792,940 |
Sector | Health | Media |
52-Week High | $129.93 | $35.24 |
52-Week Low | $83.80 | $15.42 |
Typical Hold Time | 33 Days | 85 Days |
Enterprise Value | $18.35B | $11.55B |
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
Pinterest (PINS) trades at $20.525, up 1.06% today, with a bullish technical signal from moving averages but a bearish oscillator reading. The company reported strong revenue growth to $4.22 billion in 2025, with net income of $416.86 million, and has beaten EPS estimates in recent quarters. Analyst consensus is bullish with a $27.93 price target, though insider selling and negative net cash flow trends present cautionary notes.
The outlook for PINS is positive given its revenue growth trajectory and high gross margins, but valuation multiples like a P/E of 60.38 suggest premium pricing. Risks include reliance on advertising monetization and competitive pressures. Upside potential exists if international monetization accelerates and earnings continue to exceed expectations.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →Pinterest is an online product and idea discovery platform that helps users gather ideas on everything from recipes to cook to destinations to travel to. Founded in 2010, the platform consists of a largely female audience, at roughly two thirds of its more than 365 million monthly active users. The company generates revenue by selling digital ads and is now rolling out more in-platform e-commerce features.
Read more on PINS →